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Long-term prognosis of breast cancer detected
by mammography screening or other methods
Tiina Lehtimäki1*, Mikael Lundin1, Nina Linder1, Harri Sihto2, Kaija Holli3, Taina Turpeenniemi-Hujanen4, Vesa Kataja5
, Jorma Isola6, Heikki Joensuu1,7 and Johan Lundin1,8
Abstract
Introduction: Previous studies of breast cancer have shown that patients whose tumors are detected by
mammography screening have a more favorable survival. Little is known, however, about the long-term prognostic
impact of screen detection. The purpose of the current study was to compare breast cancer-specific long-term
survival of patients whose tumors were detected in mammography screening compared with those whose tumors
were detected by other methods.
Methods: Breast cancer patients diagnosed within five specified geographical areas in Finland in 1991 and 1992 were
identified (N = 2,936). Detailed clinical, treatment and outcome data, as well as tissue samples, were collected. Women
with in situ carcinoma, distant metastases at the time of primary diagnosis and women who were not treated surgically
were excluded. The main analyses were performed after excluding patients with other malignancy or contralateral
breast cancer, followed by sensitivity analyses with different exclusion criteria. Median follow-up time was 15.4 years.
Univariate and multivariate analyses of breast cancer-specific survival were performed.
Results: Of patients included in the main analyses (n = 1,884), 22% (n = 408) of cancers were screen-detected and
78% (n = 1,476) were detected by other methods. Breast cancer-specific 15-year survival was 86% for patients with
screen-detected cancer and 66% for patients diagnosed using other methods (P < 0.0001, HR = 2.91). Similar
differences in survival were observed in women at screening age (50 to 69 years), as well as in clinically important
subgroups, such as patients with small tumors (≤ 1 cm in diameter) and without nodal involvement (N0). Women
with breast cancer diagnosed on the basis of screening mammography had a more favorable prognosis than
those diagnosed outside screening programs, following adjustments according to patient age, tumor size, axillary
lymph node status, histological grade and hormone receptor status. Significant differences in the risk of having
future contralateral breast cancer according to method of detection were not observed.
Conclusions: Breast cancer detected by mammography screening is an independent prognostic factor in breast
cancer and is associated with a more favorable survival rate as well as in long-term follow-up.
Keywords: screening, mammography, prognosis, survival analysis
Introduction
Breast cancers detected by screening mammography
have more favorable prognostic characteristics than can-
cers detected by other methods [1-9]. The tumors are
smaller, are more often well-differentiated, show less
spread to regional lymph nodes and have a lower
proliferation index [1,2,10-16]. In addition, a large pro-
portion of screen-detected tumors are of luminal type
A, and relatively few are of the human epidermal growth
factor receptor 2-positive/estrogen receptor-negative
(HER2+/ER-) molecular subtype [9]. Studies have shown
the method of detection to be an independent prognos-
tic factor, even after adjustment for a series of estab-
lished prognostic variables [9,17,18].
In a recently published study of 2,592 Dutch breast
cancer patients, screen detection was reported to be
independently associated with better breast cancer-
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specific and overall survival after a median follow-up of
11 years [18]. We observed similar results in our pre-
vious study [17] in which patients with screen-detected
breast cancer had significantly better distant disease-free
survival than patients whose tumors were detected by
other methods. Adjustments for several known prognos-
tic factors were made in both studies, which reduced
the effect of lead time and length biases. Screening as a
method of detection has been considered an indepen-
dent prognostic factor in several other studies
[3,12,19-21].
Most breast cancer recurrences occur 2 to 3 years
after diagnosis [22], but the disease recurs even 15 to 25
years after diagnosis in some patients [23-25]. A time-
dependency has been reported for prognostic factors
such as ER status, tumor size, lymph node status and
tumor grade, whereby the prognostic value may
decrease with time [22,26,27]. Researchers in only a few
studies over longer follow-up periods have analyzed the
prognostic value of the method of tumor detection.
Most of the data derived from previous studies in
which long-term outcomes of breast cancer detected
within screening programs were analyzed are from clini-
cal trials that reported mortality [28]. Only very few of
the previous studies on screen detection and breast can-
cer prognosis focused on long-term survival of the
patients (beyond 15 years from diagnosis) [3,29]. In
these studies, the favorable survival of screen-detected
cancers persisted over time. The data were adjusted for
extent of disease, but not for a more detailed clinical,
pathological or molecular profile.
There has been disagreement on the observed mortal-
ity and survival differences between patients whose
breast cancer was detected by mammography and those
whose breast cancer was detected outside screening,
owing to biases in the statistical analysis [30-33]. In the
context of patient survival, cancers found by screening
mammography are detected earlier during their natural
history and are therefore susceptible to lead time bias.
In breast cancer, the lead time is estimated to be
approximately 3 to 4 years [34]. The other main bias,
duration bias, implies that slowly growing tumors are
more likely to be detected by screening because they
remain asymptomatic but detectable by mammography
for a longer time [32,35].
Screen-detected cancers may be subject to selection
bias in that true attendees may represent not the entire
population, but rather a generally more health-conscious
population. In addition, screening may lead to detection
of indolent cancers that would never have caused symp-
tomatic disease and therefore they are overdiagnosed.
In the present study, our aim was to evaluate whether
the survival advantage of patients with screen-detected
cancers persists after long-term follow-up. For this
purpose, we analyzed an unselected nationwide series of
breast cancer patients, which was recently updated to
include long-term follow-up data. In previous studies of
screen detection and survival, various definitions of
screen-detected breast cancer have been used. In some
studies, for example, outcomes of invited women and
noninvited women have been compared [36], or interval
cancers have been included in the screen-detected
group [20,37], instead of the outcomes of true screening
attendees with the outcomes of patients with cancer
detected by other methods [36]. In the current study,
we used hospital records to retrieve information about
the method of detection and compared the survival of
true attendees with the survival of patients with cancers
detected outside screening. Survival estimates were
adjusted according to an extensive series of factors
known to reflect the extent of disease to reduce the
effect of both lead time and length time biases. In addi-
tion, we analyzed the occurrence of contralateral breast
cancer according to the method of tumor detection.
Material and methods
Patients
Five well-defined geographical areas comprising approxi-
mately 50% of the Finnish population were selected for
the study. We identified 2,936 patients diagnosed with
breast cancer in 1991 and 1992 from the files of the Fin-
nish Cancer Registry, which constitutes 53% of all
women diagnosed with breast cancer in Finland during
that time period (N = 5,551). Permission to use clinical
data and formalin-fixed, paraffin-embedded tissues for
research purposes was provided by the Ministry of
Social Affairs and Health, Finland (permission 123/08/
97). With reference to the large number of studied
cases, the authorities granted permission to use tissue
samples without individual patient consent.
Clinicopathological data were extracted from the hos-
pital records by using data collection forms, and tumor
tissue samples from each patient’s cancerous tissue were
collected for tumor microarrays [38] as previously
described in detail [9,17]. Outcome and cause of death
data were compiled from the files of the Finnish Cancer
Registry and Statistics Finland.
Of the 2,936 patients, 14 were excluded because of
zero follow-up time due to perioperative mortality or
diagnosis at autopsy. In 46 patients (2%), incorrect diag-
noses were recorded during data extraction and thus
were also excluded. The remaining 2,883 patients
formed the FinProg database, which has previously been
published and made available as an online case-match
prognostic tool http://www.finprog.org/. Of the 2,883
patients, 131 (5%) had distant metastases at the time of
diagnosis and were excluded. Patients who were not
treated surgically (n = 101, 4%) and patients with lobular
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or ductal carcinoma in situ (n = 209, 7%) were excluded.
Those with missing data on exclusion variables were
excluded, except for missing metastasis status. All of the
exclusion criteria mentioned above were used in subse-
quent analyses.
In patients with contralateral breast cancer or other
cancer, the true origin of potential distant metastases
may be difficult to determine. For the main analyses,
patients with previous, synchronous or later contralat-
eral invasive breast carcinoma were excluded (n = 349,
12%). Furthermore, we excluded patients with recent,
synchronous or later other cancers (n = 301, 10%),
except for cervical carcinoma in situ and basal cell carci-
noma. We defined other cancer as recent if it had been
diagnosed within 5 years before the index breast cancer.
Thus all patients with other carcinoma diagnosed after 1
January 1985 were excluded. The total number of
patients included in the main analyses was 1,934.
For the first sensitivity analyses, we excluded patients
with contralateral breast cancer only if it had been diag-
nosed before or at the same time as the index breast
cancer (n = 168, 6%). We also excluded patients with
other carcinoma only if it was recent (1985 and later) or
synchronous (n = 44, 2%). For the second sensitivity
analyses, we included all patients with contralateral
breast cancer or other cancer or both and used only the
primary exclusion criteria mentioned above (M+, no
surgery, ductal carcinoma in situ and lobular carcinoma
in situ). In all analyses, one patient could have been
excluded for several reasons. The consort diagrams of
the study are given in Additional file 1. We used breast
cancer-specific survival (BCSS) as an outcome measure-
ment. The median follow-up time of surviving patients
was 15.4 years.
Method of detection
A screening mammography program was launched in
Finland in 1987. During 1991 and 1992, Finnish munici-
palities were obligated by legislation to organize mam-
mography screening programs for women 50 to 59 years
of age. A few of the municipalities, however, screened
other age cohorts as well (women 40 to 49 years and/or
older than 60). The information regarding the method
of detection in the FinProg series was collected from
hospital records and from the Mass Screening Registry,
which is a department of the Finnish Cancer Registry.
Consequently, in the FinProg database, patients diag-
nosed within the mammography screening program are
patients who have been invited to have and also truly
attended screening mammography.
For cancers diagnosed on the basis of symptoms, as
interval cancers between screening rounds or for any
other reason outside the mammography screening pro-
gram, we use the term “detected outside screening” or
“non-screen-detected breast cancer.” Screening round
was not considered in this study.
Histopathological characteristics
Postsurgical tumor size was recorded according to infor-
mation extracted from hospital records. Tumor measure-
ments were done in the following order of priority: on
tumor slides by a pathologist, at the time of surgery by a
surgeon, on the basis of x-ray mammography by a radiolo-
gist or by clinical palpation. The largest tumor diameter
was recorded as its postsurgical size. In the main analyses,
there were 1,262 (65%) breast cancers whose tumor mea-
surements were done by the pathologist on the basis of
tumor slides. Similar distributions of methods of measure-
ment were seen in both screen-detected and non-screen-
detected breast cancers, where 267 (65%) and 974 (66%)
tumor measurements, respectively, were done by a pathol-
ogist and 86 (21%) and 301 (20%), respectively, were done
by a surgeon. More tumors were screen-detected when
measured by a radiologist (n = 32, 8%) than when diag-
nosed by other methods (n = 68, 5%). Palpation as a
method of measurement was used in 5 patients (1%) diag-
nosed by screening mammography compared to 51
patients (4%) diagnosed on the basis of other methods
(Additional file 2, Table S1). Histological typing and eva-
luation of the grade components (mitotic cell count,
nuclear pleomorphism and tubule formation) were usually
performed according to the World Health Organization
classification [39], although the criteria used in tumor clas-
sification cannot be stated with certainty in retrospect.
The tumors were classified into three histological types:
ductal carcinoma (not otherwise specified, including apoc-
rine, mixed mucinous and atypical medullary types), lobu-
lar carcinoma (infiltrating lobular carcinoma with variants)
and the special histological types (tubular, medullary, cri-
briform, papillary and pure mucinous carcinomas).
Laboratory methods
Immunohistochemical (IHC) staining, evaluation of pro-
tein expression and in situ hybridization were performed
as described in detail elsewhere [9,17,40,41]. According
to recent recommendations by the American Society of
Clinical Oncology, immunostaining of hormone recep-
tors was considered positive when at least 1% of the
cancer cells showed staining and negative when less
than 1% of the cancer cells were stained [42]. For the
other biomarkers, IHC expression was considered nega-
tive when less than 10% of tumor cell nuclei expressed
protein, except for Ki-67 and p53, for which we used a
cutoff of 20%.
Statistical analysis
Frequency tables were analyzed using the c2 test. Life
tables were calculated according to the Kaplan-Meier
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method. BCSS was computed from the date of the diag-
nosis until death due to breast cancer. The logrank test
was used to compare survival between subgroups. Multi-
variate survival analyses were performed using a Cox
proportional hazards model by entering the following
covariates: method of tumor detection (mammography
screening = 0, outside screening = 1), grade (well-differ-
entiated = 0, moderately or poorly differentiated = 1),
ER and progesterone receptor (PR) status (positive = 0,
negative = 1), histological type (lobular or special = 0,
ductal = 1), and age at detection grouped to account for
the nonlinear risk associated with age. The tumor size
in centimeters and the number of metastatic axillary
lymph nodes were entered into the multivariate model
as continuous variables. Multivariate analysis of the risk
of later contralateral breast cancer was performed using
logistic regression by entering the same covariates into
the model as were entered into the Cox proportional
hazards model. A P-value of 0.05 was adopted as the
limit for inclusion of a covariate. All P-values are two-
sided. STATA version 10 statistical software (StataCorp,
College Station, TX, USA) was used for the analyses.
Results
Method of tumor detection and clinicopathological
features
In the main study series (N = 1,884), 408 patients (22%)
had screen-detected breast cancer and 1,476 (78%) had
non-screen-detected breast cancer. Mammography
screening is organized mainly for women 50 to 69 years
of age. In the current series, 484 patients (26%) were
ages 50 to 59 years and 365 (19%) were ages 60 to 69
years. Of these patients, 254 (52%) and 93 (25%) were
patients with screen-detected cancer, respectively, and
230 (48%) and 272 (75%) had non-screen-detected can-
cer, respectively.
The median tumor size for the entire cohort was 20
mm. The median tumor size was 13 mm among screen-
detected tumors, and it was 20 mm in non-screen-
detected tumors. Eighty-three percent of screen-detected
tumors were 20 mm or less (T1), compared to only 53%
of non-screen-detected tumors.
Nodal involvement was less frequent in patients with
screen-detected breast cancer than in non-screen-
detected breast cancer (21% vs 37%; P < 0.001), which
was also true among women 50 to 69 years of age (20%
vs 35%; P < 0.001). Among the screen-detected cancers,
66% of tumors were 20 mm or less and had no nodal
involvement (T1N0), and only 36% of non-screen-
detected cancers belonged to this category.
The majority of screen-detected tumors were ductal
carcinomas (70%). However, the proportion of ductal
carcinomas was significantly higher (75%; P < 0.04) in
non-screen-detected cancers. The proportion of lobular
carcinomas (16%) was equal in both diagnostic groups.
Screen-detected tumors were more often of a special
histological type (14% vs 9%; P < 0.04). Similar differ-
ences in histological profile were seen in the 50- to 69-
year-old age cohort (ductal: 70% vs 73%; lobular: 16% vs
19%; special type: 14% vs 8%; P = 0.02).
Tumors detected by mammography screening were
more often of a lower grade of differentiation. There
were 129 grade 1 breast cancers (32%) in the screen-
detected group and 241 (16%) among tumors detected
by other methods (P < 0.001). Correspondingly, screen-
detected cancers were less often grade 2 or 3 tumors (n
= 202, 49%) than were non-screen-detected cancers (n =
841, 57%) (P < 0.001). However, this association wea-
kened with increasing tumor size (Additional file 2,
Table S2). In T1N0 tumors, 36% of screen-detected
tumors were well-differentiated, but only 22% in the
non-screen-detected group were. In patients with larger
tumors, such as T2 tumors (21 to 50 mm), the propor-
tion of G1 tumors was equal in both diagnostic groups
(11%) and the proportion of G2-3 tumors was 75% in
screen-detected tumors compared to 64% in non-
screen-detected tumors (P = 0.77).
Screen detection was associated with hormone recep-
tor status (ER and PR), although in analyses consisting
of all age groups, the association was weak (P = 0.038
and P = 0.094, respectively). In women at screening age
(50 to 69 years), there were only 9% ER- tumors in
screen-detected tumors compared to 19% in non-
screen-detected tumors (P = 0.002). Similar differences
were seen according to PR status (P < 0.001).
No statistically significant association between screen
detection and HER2 gene amplification or p53 expres-
sion was seen in any of the analyzed age groups. Some-
what fewer Ki-67-positive tumors were seen in screen-
detected breast cancers compared to those detected out-
side screening (18% vs 26%), but the association was not
statistically significant (P = 0.08).
Adjuvant systemic therapy was given less frequently to
patients with screen-detected breast cancer than to
women with non-screen-detected breast cancer (22% vs
41%; P < 0.001). The use of adjuvant systemic therapy
was not known in 5 patients (1%) with screen-detected
cancers and in 40 patients (3%) with non-screen-
detected cancers.
In women 50 to 69 years of age, screen detection was
statistically significantly associated with smaller primary
tumor size, less frequent lymph node metastasis, special
histological type, lower grade of differentiation and posi-
tive hormone receptor status (ER and PR) compared
with non-screen-detected cancers. The distribution of
clinicopathological features in women with breast cancer
diagnosed by screening mammography and by other
methods is shown in Table 1.
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Table 1 Descriptive statistics for main analyses (N = 1,884)
All age groups Ages 50 to 69 years
Factor Screening, n (%)a
(n = 408)
Outside screening, n (%)
(n = 1,476)
P value Screening, n (%)
(n = 347)
Outside screening, n (%)
(n = 502)
P value
Primary tumor diameter (mm) < 0.001 < 0.001
≤ 10 158 (39) 207 (14) 143 (41) 82 (16)
11 to 20 179 (44) 576 (39) 147 (42) 204 (41)
21 to 50 55 (13) 581 (39) 42 (12) 183 (36)
> 50 2 (0) 66 (4) 1 (0) 21 (4)
N.A. 14 (3) 46 (3) 14 (4) 12 (2)
Nodal status < 0.001 < 0.001
Negative 317 (77) 862 (58) 273 (79) 321 (64)
Positive 85 (21) 552 (37) 69 (20) 178 (35)
N.A. 6 (1) 62 (4) 5 (1) 3 (0)
Histological type 0.04 0.02
Ductal 287 (70) 1,104 (75) 243 (70) 365 (73)
Lobular 65 (16) 232 (16) 55 (16) 95 (19)
Special type 56 (14) 139 (9) 49 (14) 41 (8)
N.A. 0 1 (0) 0 1 (0)
Histological grade < 0.001 < 0.001
1 129 (32) 241 (16) 111 (32) 85 (17)
2 147 (36) 515 (35) 123 (35) 172 (34)
3 55 (13) 326 (22) 43 (12) 115 (23)
N.A. 77 (19) 394 (27) 70 (20) 130 (26)
ER content 0.038 0.002
Negative 40 (10) 232 (16) 31 (9) 94 (19)
Positive 204 (50) 802 (54) 172 (50) 260 (52)
N.A. 164 (40) 442 (30) 144 (41) 148 (29)
PR content 0.094 < 0.001
Negative 79 (19) 392 (27) 64 (18) 171 (34)
Positive 161 (39) 620 (42) 132 (38) 173 (34)
N.A. 168 (41) 464 (31) 151 (44) 158 (31)
HER2
Amplification 0.09 0.19
Negative 217 (53) 852 (58) 176 (51) 293 (58)
Positive 37 (9) 202 (14) 32 (9) 72 (14)
N.A. 154 (38) 422 (29) 139 (40) 137 (27)
Expression 0.25 0.33
Negative 218 (53) 889 (60) 179 (52) 299 (60)
Positive 39 (10) 198 (13) 33 (10) 69 (14)
N.A. 151 (37) 389 (26) 135 (39) 134 (27)
Ki-67 0.08 0.07
Negative 155 (38) 615 (42) 133 (38) 209 (42)
Positive 73 (18) 379 (26) 54 (16) 121 (24)
N.A. 180 (44) 482 (33) 160 (46) 172 (34)
p53 0.63 0.21
Negative 171 (42) 786 (53) 145 (42) 254 (51)
Positive 38 (9) 192 (13) 31 (9) 73 (15)
N.A. 199 (49) 498 (34) 171 (49) 175 (35)
Adjuvant systemic therapy < 0.001 < 0.001
Not given 314 (77) 827 (56) 271 (78) 297 (59)
Given 89 (22) 609 (41) 72 (21) 197 (39)
N.A. 5 (1) 40 (3) 4 (1) 8 (2)
ER = estrogen receptor; PR = progesterone receptor; N.A. = not available. aPercentages may not equal 100% due to rounding.
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Method of detection and breast cancer survival
Women with screen-detected breast cancer had more
favorable BCSS than patients with non-screen-detected
cancer. The 15-year BCSS rate for patients with screen-
detected breast cancer was 86%, and for patients with
non-screen-detected breast cancer it was 66% (P <
0.0001, RR = 2.91, RR = risk ratio). The survival advan-
tage was seen in tumor size categories 1 to 10 mm, 11
to 20 mm and 21 to 50 mm (Figure 1). Only two
patients available for analysis in the screen-detected
group had tumors larger than 50 mm, which did not
allow a statistical comparison. Women with screen-
Tumor size 21 50mmTumor size 11 20mm
0%
25%
50%
75%
100%
0 5 10 15 20
Follow-up (years)
Tumor size 1-10mm
0%
25%
50%
75%
100%
0 5 10 15 20
Follow-up (years)
Tumor size all
No. At risk
screened 408 379 345 313
non-scr 1476 1086 819 658
LogRank ChiSquared: 60,51  p<.0001  RR:2.91
158 153 142 132
207 175 143 116
LogRank ChiSquared: 4,73  p=.0296  RR:2.04
0%
25%
50%
75%
100%
0 5 10 15 20
Follow-up (years)
  -
0%
25%
50%
75%
100%
0 5 10 15 20
Follow-up (years)
  -
No. At risk
screened 179 163 148 133
non-scr 576 465 358 297
LogRank ChiSquared: 7,39  p=.0066  RR:1.75
55 49 41 37
581 392 281 214
LogRank ChiSquared: 6,86  p<=.0088  RR:2.08
Figure 1 Breast cancer-specific survival by primary tumor size and mode of detection. Solid lines represent cancers detected by
mammography screening, dashed lines represent cancers detected outside screening.
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detected T2 category tumors (21 to 50 mm) had prog-
noses similar to those of patients with non-screen-
detected T1 category tumors (1 to 20 mm) (15-year
BCSS 76.6% vs 77%; P = 0.863 and RR = 0.95) (Table 2).
Influence of screening on outcome according to nodal
status
This study included 1,203 (62%) node-negative and 654
(34%) node-positive breast cancer patients. Among the
node-negative breast cancer patients, breast cancer was
screen-detected in 317 patients (78%) and non-screen-
detected in 862 patients (58%) (P < 0.001). In patients with
screen-detected node-negative breast cancer, 15-year
BCSS was 91% compared to 77% in the non-screen-
detected group (P < 0.0001 and RR = 3). Patients with
screen-detected, node-positive breast cancer had a survival
advantage compared to patients diagnosed by other meth-
ods (71% vs 51%, respectively; P = 0.0011 and RR = 1.95).
Influence of age at diagnosis on outcome
In this study, there were 873 patients (45%) ages 50 to
69 years, of whom 347 (40%) were diagnosed by screen-
ing and 502 (58%) were diagnosed on the basis of other
methods. There was a statistically significant difference
in 15-year BCSS between the two subgroups (15-year
BCSS 86% for patients with screen-detected tumors and
68% for patients diagnosed by other methods; P <
0.0001 and RR = 2.61). Similar differences in survival
were observed in all other age cohorts (Table 3).
Multivariate survival analyses
Screening mammography is commonly offered to
women 50 to 69 years of age. Because the proportion of
screen-detected cancers was different according to age
groups, and since screen-detected tumors were smaller,
less often node-positive, less often of the ductal type,
more differentiated, and associated with a more favor-
able hormonal status, we performed a multivariate ana-
lysis to adjust for these factors. As a result, the method
of tumor detection was an independent prognostic fac-
tor, with a hazard ratio (HR) of 1.69 (95% CI = 1.06 to
2.70) between patients whose tumors were detected out-
side screening and those whose tumors were screen-
detected. Tumor size, nodal status, tumor grade and
HER2 amplification OK were also independent of other
variables (Table 4). The HR for the method of detection
was 1.48 (95% CI = 0.97 to 2.25) in the first sensitivity
analysis and 1.45 (95% CI = 0.97 to 2.17) in the second
sensitivity analysis.
Contralateral breast cancer
Differences in the probability of having future contralat-
eral breast cancer between screen-detected and non-
screen-detected breast cancer patients during the 15-
year follow-up time were assessed. For this analysis, we
used the same exclusion criteria that we applied in the
main analysis, with the exception of later contralateral
breast cancers. Without any adjustments according to
other variables, there were no significant differences if
the primary breast cancer was diagnosed by screening
mammography or by other methods (7.3% vs 6.8%,
respectively; P = 0.74 and OR = 0.96). When patients 50
to 69 years of age were analyzed, the results were similar
(7.0% vs 7.9%, respectively; P = 0.60, respectively). After
adjustments according to the same covariates as those
used in the Cox multivariate survival analyses, the risk
Table 2 Breast cancer-specific survival according to primary tumor diameter
Screening Outside screening
Primary tumor diameter (mm) At risk (n) 15-year survival (%) At risk (n) 15-year survival (%) P value RR
All age groups
≤ 10 132 92.1 116 83.9 0.0296 2.04
11 to 20 133 84 297 74.5 0.0066 1.75
21 to 50 37 76.6 214 56.5 0.0088 2.08
> 50 N.A. N.A. 19 34.1 N.A. N.A.
Ages 50 to 69 years
≤ 10 122 92.1 54 83.1 0.0343 2.25
11 to 20 110 81.5 123 74.6 0.0764 1.52
21 to 50 30 77.7 89 59.4 0.0325 1.02
> 50 N.A. N.A. 5 35.7 N.A. N.A.
Node-negative ages 50 to 69 years
≤ 10 114 93.7 48 84 0.021 2.66
11 to 20 84 87 89 79.3 0.0534 1.85
21 to 50 19 90.7 58 70.9 0.0769 2.79
> 50 N.A. N.A. 2 50 N.A. N.A.
N.A. = data not available because screen-detected tumors were rarely > 50 mm; RR = risk ratio.
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of having later contralateral breast cancer was slightly
increased in patients with breast cancer detected outside
screening compared to patients with screen-detected
breast cancer (95% CI = 0.55 to 2.57 and OR = 1.18),
but the difference was not statistically significant.
Discussion
In the current study, we have shown that the outcome
of breast cancer is significantly better in patients with
mammography screen-detected tumors than in patients
with tumors detected by other methods, even beyond 15
years after diagnosis. After adjustment for a series of
potential confounders, patients whose tumors were
detected during screening mammography had an
approximately 41% lower risk of dying as a result of
breast cancer than did those whose tumors were
detected outside screening. These results are in accord
with those of our previous studies [9,17] in which we
found significant survival differences over postdiagnostic
follow-up durations up to 10 years.
The survival difference could not be explained by lead
time- and length bias-related variables, such as extent of
disease, histopathological and molecular prognostic fac-
tors. Similar results have been reported by others
[3,18,19,29] who have shown the method of detection to
be an independent prognostic factor. An adjusted risk
Table 3 Breast cancer-specific survival by method of detection and age at diagnosis
Screening Outside screening
Survival (%) Survival (%)
Age at diagnosis (years) Patients (n) 5 years 10 years 15 years Patients (n) 5 years 10 years 15 years
Node-negative and node-positive
≤ 39 2 N.A. N.A. N.A. 118 81.4 63.5 57.3
40 to 49 47 100 93.5 93.5 362 85.6 75.8 71.3
50 to 59 254 94.1 89.6 86.3 230 84.2 77.1 71.5
60 to 69 93 97.8 92.1 84.9 272 83.3 71.2 65.8
≥ 70 12 N.A. N.A. N.A. 494 80.4 69.1 60.8
Node-negative
≤ 39 1 N.A. N.A. N.A. 64 92.2 81.2 76.3
40 to 49 34 100 97.1 97.1 195 92.8 85.6 82.5
50 to 59 190 98.4 95.2 92.4 150 92 86.5 82.3
60 to 69 83 98.9 92.5 87.2 171 86.1 79.1 72.1
≥ 70 9 N.A. N.A. N.A. 282 88.6 78 70.7
Node-positive
≤ 39 1 N.A. N.A. N.A. 54 72.2 46.3 38.6
40 to 49 12 100 91.7 91.7 165 76.9 64 57.8
50 to 59 61 83.4 75 69.9 79 69.5 59.2 50.9
60 to 69 8 100 100 71.4 99 78.4 58.4 55.6
≥ 70 3 N.A. N.A. N.A. 155 66 55.5 45.4
N.A. = data not available because screening was rarely performed in women ages ≤ 39 and ≥ 70.
Table 4 Cox multivariable analysis
Variable HR (95% CI) P value
Detection outside screening 1.69 (1.06 to 2.70) 0.028
Tumor size (per cm) 1.02 (1.01 to 1.03) < 0.001
Positive lymph nodes (n/metastatic node) 1.31 (1.10 to 1.17) < 0.001
Histological grade (grade II vs grade III vs grade I) 2.54 (1.52 to 4.25) < 0.001
PR (negative vs positive) 1.23 (0.92 to 1.64) 0.154
HER2 amplification (positive vs negative) 1.45 (1.06 to 1.97) 0.019
Age at diagnosis (years)
≤ 39a 1.00
40 to 49 0.62 (0.28 to 1.00) 0.051
50 to 59 0.82 (0.50 to 1.34) 0.437
60 to 69 0.92 (0.57 to 1.49) 0.733
≥ 70 1.13 (0.70 to 1.83) 0.605
aReference category.
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decrease ranging from 21% to 48% for patients detected
within screening has been reported, which is similar to
the effect size found in the current study [3,18,19].
In agreement with previous studies, we found that
screen-detected tumors were smaller and were less fre-
quently node-positive than tumors detected outside
screening. Screen-detected tumors were more often
well-differentiated, of special histological type, hormone
receptor-positive and showed lower proliferation as
measured by Ki-67 expression. The only examined bio-
marker that was not significantly associated with the
method of detection was HER2 amplification. A similar
finding has previously been reported for HER2 expres-
sion [2,6].
The adjusted HR (1.69) between patients with screen-
detected and non-screen-detected cancers according to
BCSS was somewhat lower, with a median follow-up of
15.4 years compared to the HR (2.1) after 9.5 years fol-
low-up in our previous study [17]. This finding could
potentially be explained by a large proportion of patients
who were excluded (contralateral breast cancer or other
cancer) during the extended follow-up in the main ana-
lyses. It is not supported by the sensitivity analyses,
however, because the HR was lower (1.47) when patients
with contralateral cancers were included.
The risk of contralateral breast cancer among breast
cancer survivors is reportedly two- to sixfold the risk of
breast cancer in the general population [43]. The risk of
having contralateral breast cancer among breast cancer
survivors is associated with lobular or inflammatory his-
tology of the primary breast cancer, family history of
breast cancer and young age at the time of primary
diagnosis [44-47]. To the best of our knowledge, the
association between the method of detection of primary
cancer and the risk of contralateral breast cancer has
not been investigated previously. In current study, we
found that the risk for contralateral breast cancer was
similar in patients with screen-detected and non-screen-
detected cancers. However, the risk of contralateral
breast cancer is reported to be significantly higher
among women with primary in situ cancer [48]. The
proportion of in situ cancers is higher in screen-
detected than in non-screen-detected cancers. Only
patients with invasive breast cancers were included in
the current study. Whether the risk of contralateral
breast cancer is altered according to the method of
detection in women with primary in situ cancer remains
to be investigated. According to this study, the follow-
up for contralateral breast cancer should be similar in
patients with screen-detected and non-screen-detected
invasive breast cancers.
In the current study, screen-detected cancer was
defined according to true attendance at mammography
screening. All other breast cancers, including those of
patients who did not undergo mammography, were con-
sidered non-screen-detected. If we had included nonat-
tendees in the screen-detected group, the survival
estimates could be distorted, thus underestimating the
survival advantage of screening. In a previous study,
breast cancer mortality among the women invited to
have mammographies was reduced by 22%, whereas the
mortality reduction was 28% among true attendees [49].
The use of adjuvant therapies was rather homoge-
neous during 1991 and 1992 in Finland. In this cohort,
adjuvant therapy was given less frequently to patients
with screen-detected tumors than to patients with breast
cancer diagnosed by other methods. Thus the use of
adjuvant therapies does not explain the survival advan-
tage associated with screening in this study.
Although there were significant differences in the pro-
portion of many commonly used prognostic factors
between screen-detected and non-screen-detected
tumors, the frequency of lobular carcinoma was similar
in both groups. Lobular carcinomas are often difficult to
detect by mammography because they are radiologically
elusive [50,51]. Lobular carcinomas may also be difficult
to detect clinically because they less commonly form a
palpable mass [52], which may in part explain the simi-
lar proportion of lobular carcinomas in both groups.
Although we were able to adjust the HRs for the
method of detection for an extensive series of known
prognostic factors, survival differences remain to be
explained. More detailed tumor profiling might aid in
characterizing tumors and should be studied in future
projects. The value of some commonly used prognostic
factors is observed to diminish over prolonged follow-up
times. In the present study, the screening benefit
remained after long-term follow-up. According to this
study, patients with screen-detected breast cancer may
be overtreated if screening as a method of detection is
not taken into account in risk estimation and therapy
decision-making.
Conclusions
The method of detection is an independent prognostic
factor for long-term survival among breast cancer
patients. According to this study, screening as a method
of detection may be considered a favorable prognostic
factor in risk estimation and therapy decision-making to
avoid overtreatment of screen-detected breast cancers.
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1,884). Table S2 Adjustment according to tumor size after analyzing
proportion of different grades in screen-detected and non-screen-
detected patients (exclusions according to main analyses, N = 1,884).
Abbreviations
CISH: chromogenic in situ hybridization; ER: estrogen receptor; HER2: human
epidermal growth factor receptor 2; PR: progesterone receptor.
Acknowledgements
This work was supported by the Sigrid Jusèlius Foundation (to JL and HJ),
the Cancer Society of Finland (to JL and HJ), the Academy of Finland (to HJ),
Helsinki University Central Hospital Research Funds (to JL and HJ), the
Biomedicum Helsinki Foundation (to TL) and Finska Läkaresällskapet (to JL,
ML and NL).
Author details
1Institute for Molecular Medicine Finland (FIMM), University of Helsinki,
Biomedicum Helsinki 2U, Tukholmankatu 8, PO Box 20, FI-00014 Helsinki,
Finland. 2Molecular Cancer Biology Program, Biomedicum Helsinki, University
of Helsinki, Tukholmankatu 8, PO Box 20, FI-00014, Helsinki, Finland.
3Departments of Palliative Medicine and Oncology, Tampere University
Hospital and University of Tampere, Teiskontie 35, PO Box 2000, FI-33521,
Tampere, Finland. 4Department of Oncology and Hematology, Oulu
University Central Hospital, Kajaanintie 50, PO Box 20, FI-90029, Oulu, Finland.
5Cancer Center, Kuopio University Central Hospital, Puijonlaaksontie 2, PO
Box 1777, FI-70211, Kuopio, Finland. 6Institute of Medical Technology,
University of Tampere and Tampere University Hospital, Biokatu 8-12, PO Box
2000, FI-33520,Tampere, Finland. 7Department of Oncology, Helsinki
University Central Hospital, Haartmaninkatu 4, PO Box 180, FI-00029, Helsinki,
Finland. 8Division of Global Health, Karolinska Institutet, SE-17177, Stockholm,
Sweden.
Authors’ contributions
TL, HJ and JL designed the study and drafted the manuscript. HJ initiated
the FinProg study and organized the collection of clinical data. JL, ML, TL,
KH, LE, VK, TTH and JI collected the clinical data. JI organized the collection
of tumor samples. TL collected the tissue for tissue microarrays. JI, HS and
NL interpreted the results of the immunohistochemical and in situ
hybridization analysis. TL and JL performed the statistical analyses. All
authors critically revised the manuscript and approved its final form.
Competing interests
The authors declare that they have no competing interests.
Received: 1 July 2011 Revised: 22 December 2011
Accepted: 28 December 2011 Published: 28 December 2011
References
1. Porter PL, El-Bastawissi AY, Mandelson MT, Lin MG, Khalid N, Watney EA,
Cousens L, White D, Taplin S, White E: Breast tumor characteristics as
predictors of mammographic detection: comparison of interval- and
screen-detected cancers. J Natl Cancer Inst 1999, 91:2020-2028.
2. Dawson SJ, Duffy SW, Blows FM, Driver KE, Provenzano E, LeQuesne J,
Greenberg DC, Pharoah P, Caldas C, Wishart GC: Molecular characteristics
of screen-detected vs symptomatic breast cancers and their impact on
survival. Br J Cancer 2009, 101:1338-1344.
3. Shen Y, Yang Y, Inoue LY, Munsell MF, Miller AB, Berry DA: Role of
detection method in predicting breast cancer survival: analysis of
randomized screening trials. J Natl Cancer Inst 2005, 97:1195-1203.
4. Burrell HC, Sibbering DM, Wilson AR, Pinder SE, Evans AJ, Yeoman LJ,
Elston CW, Ellis IO, Blamey RW, Robertson JF: Screening interval breast
cancers: mammographic features and prognosis factors. Radiology 1996,
199:811-817.
5. Cady B, Stone MD, Schuler JG, Thakur R, Wanner MA, Lavin PT: The new
era in breast cancer: invasion, size, and nodal involvement dramatically
decreasing as a result of mammographic screening. Arch Surg 1996,
131:301-308.
6. Pálka I, Kelemen G, Ormándi K, Lázár G, Nyári T, Thurzó L, Kahán Z: Tumor
characteristics in screen-detected and symptomatic breast cancers.
Pathol Oncol Res 2008, 14:161-167.
7. Cady B: New era in breast cancer: impact of screening on disease
presentation. Surg Oncol Clin N Am 1997, 6:195-202.
8. Paci E, Duffy SW, Giorgi D, Zappa M, Crocetti E, Vezzosi V, Bianchi S,
Cataliotti L, del Turco MR: Are breast cancer screening programmes
increasing rates of mastectomy? Observational study. BMJ 2002, 325:418.
9. Sihto H, Lundin J, Lehtimäki T, Sarlomo-Rikala M, Bützow R, Holli K, Sailas L,
Kataja V, Lundin M, Turpeenniemi-Hujanen T, Isola J, Heikkilä P, Joensuu H:
Molecular subtypes of breast cancers detected in mammography
screening and outside of screening. Clin Cancer Res 2008, 14:4103-4110.
10. Crosier M, Scott D, Wilson RG, Griffiths CDM, May FEB, Westley BR:
Differences in Ki67 and c-erbB2 expression between screen-detected
and true interval breast cancers. Clin Cancer Res 1999, 5:2682-2688.
11. Groenendijk RP, Bult P, Tewarie L, Peer PG, van der Sluis RF, Ruers TJ,
Wobbes T: Screen-detected breast cancers have a lower mitotic activity
index. Br J Cancer 2000, 82:381-384.
12. Dong W, Berry DA, Bevers TB, Kau SW, Hsu L, Theriault RL, Shen Y:
Prognostic role of detection method and its relationship with tumor
biomarkers in breast cancer: the University of Texas M.D. Anderson
Cancer Center experience. Cancer Epidemiol Biomarkers Prev 2008,
17:1096-1103.
13. Ernst MF, Roukema JA, Coebergh JW, Repelaer van Driel OJ, van Beek MW,
van der Sangen MJ, Voogd AC: Breast cancers found by screening: earlier
detection, lower malignant potential or both? Breast Cancer Res Treat
2002, 76:19-25.
14. Gabriel H, Wilson TE, Helvie MA: Breast cancer in women 65-74 years old:
earlier detection by mammographic screening. AJR Am J Roentgenol 1997,
168:23-27.
15. Anttinen J, Kuopio T, Nykanen M, Torkkeli H, Saari U, Juhola M: Her-2/neu
oncogene amplification and protein over-expression in interval and
screen-detected breast cancers. Anticancer Res 2003, 23:4213-4218.
16. Klemi PJ, Toikkanen S, Räsänen O, Parvinen I, Joensuu H: Mammography
screening interval and the frequency of interval cancers in a population-
based screening. Br J Cancer 1997, 75:762-766.
17. Joensuu H, Lehtimäki T, Holli K, Elomaa L, Turpeenniemi-Hujanen T,
Kataja V, Anttila A, Lundin M, Isola J, Lundin J: Risk for distant recurrence
of breast cancer detected by mammography screening or other
methods. JAMA 2004, 292:1064-1073.
18. Mook S, Van ‘t Veer LJ, Rutgers EJ, Ravdin PM, van de Velde AO, van
Leeuwen FE, Visser O, Schmidt MK: Independent prognostic value of
screen detection in invasive breast cancer. J Natl Cancer Inst 2011,
103:585-597.
19. Wishart GC, Greenberg DC, Britton PD, Chou P, Brown CH,
Purushotham AD, Duffy SW: Screen-detected vs symptomatic breast
cancer: is improved survival due to stage migration alone? Br J Cancer
2008, 98:1741-1744.
20. Immonen-Räihä P, Kauhava L, Parvinen I, Holli K, Kronqvist P, Pylkkänen L,
Helenius H, Kaljonen A, Räsänen O, Klemi PJ: Mammographic screening
reduces risk of breast carcinoma recurrence. Cancer 2005, 103:474-482.
21. Nagtegaal ID, Allgood PC, Duffy SW, Kearins O, Sullivan EO, Tappenden N,
Wallis M, Lawrence G: Prognosis and pathology of screen-detected
carcinomas: how different are they? Cancer 2011, 117:1360-1368.
22. Jatoi I, Anderson WF, Jeong JH, Redmond CK: Breast cancer adjuvant
therapy: time to consider its time-dependent effects. J Clin Oncol 2011,
29:2301-2304, A published erratum appears in J Clin Oncol 2011, 29:3948.
23. Brenner H, Hakulinen T: Are patients diagnosed with breast cancer before
age 50 years ever cured? J Clin Oncol 2004, 22:432-438.
24. Joensuu H, Pylkkänen L, Toikkanen S: Late mortality from pT1N0M0 breast
carcinoma. Cancer 1999, 85:2183-2189.
25. Joensuu H, Toikkanen S: Cured of breast cancer? J Clin Oncol 1995,
13:62-69.
26. Warwick J, Tabár L, Vitak B, Duffy SW: Time-dependent effects on survival
in breast carcinoma: results of 20 years of follow-up from the Swedish
Two-County Study. Cancer 2004, 100:1331-1336.
27. Anderson WF, Chen BE, Jatoi I, Rosenberg PS: Effects of estrogen receptor
expression and histopathology on annual hazard rates of death from
breast cancer. Breast Cancer Res Treat 2006, 100:121-126.
28. Tabár L, Vitak B, Chen TH, Yen AM, Cohen A, Tot T, Chiu SY, Chen SL,
Fann JC, Rosell J, Fohlin H, Smith RA, Duffy SW: Swedish Two-County Trial:
Lehtimäki et al. Breast Cancer Research 2011, 13:R134
http://breast-cancer-research.com/content/13/6/R134
Page 10 of 11
impact of mammographic screening on breast cancer mortality during 3
decades. Radiology 2011, 260:658-663.
29. Tabár L, Duffy SW, Vitak B, Chen HH, Prevost TC: The natural history of
breast carcinoma: what have we learned from screening? Cancer 1999,
86:449-462.
30. Woloshin S, Schwartz LM: The benefits and harms of mammography
screening: understanding the trade-offs. JAMA 2010, 303:164-165.
31. Murphy AM: Mammography screening for breast cancer: a view from 2
worlds. JAMA 2010, 303:166-167.
32. Kopans DB, Monsees B, Feig SA: Screening for cancer: when is it valid?
Lessons from the mammography experience. Radiology 2003,
229:319-327.
33. Zahl PH, Strand BH, Maehlen J: Incidence of breast cancer in Norway and
Sweden during introduction of nationwide screening: prospective
cohort study. BMJ 2004, 328:921-924.
34. de Koning HJ: Why improvement in survival of screen-detected cases is
not necessarily equivalent to benefit? Breast 2003, 12:299-301.
35. Duffy SW, Nagtegaal ID, Wallis M, Cafferty FH, Houssami N, Warwick J,
Allgood PC, Kearins O, Tappenden N, O’Sullivan E, Lawrence G: Correcting
for lead time and length bias in estimating the effect of screen
detection on cancer survival. Am J Epidemiol 2008, 168:98-104.
36. Berg WA: Benefits of screening mammography. JAMA 2010, 303:168-169.
37. Olivotto IA, Mates D, Kan L, Fung J, Samant R, Burhenne LJ: Prognosis,
treatment, and recurrence of breast cancer for women attending or not
attending the Screening Mammography Program of British Columbia.
Breast Cancer Res Treat 1999, 54:73-81.
38. Kononen J, Bubendorf L, Kallioniemi A, Bärlund M, Schraml P, Leighton S,
Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP: Tissue microarrays for
high-throughput molecular profiling of tumor specimens. Nat Med 1998,
4:844-847.
39. World Health Organization: The World Health Organization Histological
Typing of Breast Tumors-Second Edition. Am J Clin Pathol 1982,
78:806-816.
40. Joensuu H, Isola J, Lundin M, Salminen T, Holli K, Kataja V, Pylkkänen L,
Turpeenniemi-Hujanen T, von Smitten K, Lundin J: Amplification of erbB2
and erbB2 expression are superior to estrogen receptor status as risk
factors for distant recurrence in pT1N0M0 breast cancer: a nationwide
population-based study. Clin Cancer Res 2003, 9:923-930.
41. Tanner M, Gancberg D, Di Leo A, Larsimont D, Rouas G, Piccart MJ, Isola J:
Chromogenic in situ hybridization: a practical alternative for
fluorescence in situ hybridization to detect HER-2/neu oncogene
amplification in archival breast cancer samples. Am J Pathol 2000,
157:1467-1472.
42. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S,
Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R,
Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A,
Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P,
Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC: American
Society of Clinical Oncology/College Of American Pathologists guideline
recommendations for immunohistochemical testing of estrogen and
progesterone receptors in breast cancer. J Clin Oncol 2010, 28:2784-2795,
A published erratum appears in J Clin Oncol 2010, 28:3543.
43. Rubino C, Arriagada R, Delaloge S, Lê MG: Relation of risk of contralateral
breast cancer to the interval since the first primary tumour. Br J Cancer
2010, 102:213-219.
44. Chen Y, Thompson W, Semenciw R, Mao Y: Epidemiology of contralateral
breast cancer. Cancer Epidemiol Biomarkers Prev 1999, 8:855-861.
45. Horn PL, Thompson WD: Risk of contralateral breast cancer: associations
with histologic, clinical, and therapeutic factors. Cancer 1988, 62:412-424.
46. Schairer C, Brown LM, Mai PL: Inflammatory breast cancer: high risk of
contralateral breast cancer compared to comparably staged non-
inflammatory breast cancer. Breast Cancer Res Treat 2011, 129:117-124.
47. Yi M, Meric-Bernstam F, Middleton LP, Arun BK, Bedrosian I, Babiera GV,
Hwang RF, Kuerer HM, Yang W, Hunt KK: Predictors of contralateral breast
cancer in patients with unilateral breast cancer undergoing contralateral
prophylactic mastectomy. Cancer 2009, 115:962-971.
48. Habel LA, Moe RE, Daling JR, Holte S, Rossing MA, Weiss NS: Risk of
contralateral breast cancer among women with carcinoma in situ of the
breast. Ann Surg 1997, 225:69-75.
49. Sarkeala T, Heinävaara S, Anttila A: Organised mammography screening
reduces breast cancer mortality: a cohort study from Finland. Int J
Cancer 2008, 122:614-619.
50. Li CI, Anderson BO, Daling JR, Moe RE: Trends in incidence rates of
invasive lobular and ductal breast carcinoma. JAMA 2003, 289:1421-1424.
51. Ma L, Fishell E, Wright B, Hanna W, Allan S, Boyd NF: Case-control study of
factors associated with failure to detect breast cancer by
mammography. J Natl Cancer Inst 1992, 84:781-785.
52. Lopez JK, Bassett LW: Invasive lobular carcinoma of the breast: spectrum
of mammographic, US, and MR imaging findings. Radiographics 2009,
29:165-176.
doi:10.1186/bcr3080
Cite this article as: Lehtimäki et al.: Long-term prognosis of breast
cancer detected by mammography screening or other methods. Breast
Cancer Research 2011 13:R134.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Lehtimäki et al. Breast Cancer Research 2011, 13:R134
http://breast-cancer-research.com/content/13/6/R134
Page 11 of 11
